All Stories

  1. A variant NS1 protein from H5N2 avian influenza virus suppresses PKR activation and promotes replication and virulence in mammals
  2. Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine
  3. Detection of Velogenic Avian Paramyxoviruses in Rock Doves in New York City, New York
  4. Limited extent and consequences of pancreatic SARS-CoV-2 infection
  5. Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission
  6. Profiling Selective Packaging of Host RNA and Viral RNA Modification in SARS-CoV-2 Viral Preparations
  7. Functional Effects of Cardiomyocyte Injury in COVID-19
  8. Advances and gaps in SARS-CoV-2 infection models
  9. Tox2 is required for the maintenance of GC T FH cells and the generation of memory T FH cells
  10. Interaction between NS1 and Cellular MAVS Contributes to NS1 Mitochondria Targeting
  11. Restriction factor compendium for influenza A virus reveals a mechanism for evasion of autophagy
  12. Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity
  13. Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression
  14. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics
  15. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation
  16. Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model
  17. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
  18. Mass Cytometry Defines Virus-Specific CD4+ T Cells in Influenza Vaccination
  19. Real-Time Investigation of a Large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology
  20. Animal models for COVID-19
  21. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
  22. An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening
  23. Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection
  24. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
  25. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial
  26. Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts
  27. Viral Determinants in H5N1 Influenza A Virus Enable Productive Infection of HeLa Cells
  28. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge
  29. Innate Immune Response to Influenza Virus at Single-Cell Resolution in Human Epithelial Cells Revealed Paracrine Induction of Interferon Lambda 1
  30. Host-Specific NS5 Ubiquitination Determines Yellow Fever Virus Tropism
  31. STAT2 is a determinant of yellow fever virus host tropism
  32. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model
  33. Diminished B-Cell Response After Repeat Influenza Vaccination
  34. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance
  35. A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study
  36. Microbiome disturbance and resilience dynamics of the upper respiratory tract in response to influenza A virus infection in humans and ferrets
  37. Analyses of Cellular Immune Responses in Ferrets Following Influenza Virus Infection
  38. Assessment of Influenza Virus Hemagglutinin Stalk-Specific Antibody Responses
  39. Timing of Influenza Vaccine Response in Patients That Receive Autologous Hematopoietic Cell Transplantation
  40. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins
  41. A point mutation in the polymerase protein PB2 allows a reassortant H9N2 influenza isolate of wild-bird origin to replicate in human cells
  42. ICOS+PD-1+CXCR3+ T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination
  43. Suppression of dendritic cell necroptosis by pandemic influenza virus
  44. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations
  45. Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine
  46. Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets
  47. Meta- and Orthogonal Integration of Influenza “OMICs” Data Defines a Role for UBR4 in Virus Budding
  48. Interactive Big Data Resource to Elucidate Human Immune Pathways and Diseases
  49. Human Dendritic Cell Response Signatures Distinguish 1918, Pandemic, and Seasonal H1N1 Influenza Viruses
  50. Regulation of necroptosis as a viral immune antagonistic mechanism (INM3P.361)
  51. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency
  52. The Nucleoprotein of Newly Emerged H7N9 Influenza A Virus Harbors a Unique Motif Conferring Resistance to Antiviral Human MxA
  53. A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory
  54. Influenza A Virus Transmission Bottlenecks Are Defined by Infection Route and Recipient Host
  55. Distinct Patterns of B-Cell Activation and Priming by Natural Influenza Virus Infection Versus Inactivated Influenza Vaccination
  56. Immunologic Characterization of a Rhesus Macaque H1N1 Challenge Model for Candidate Influenza Virus Vaccine Assessment
  57. Effect of Cholecalciferol Supplementation on Inflammation and Cellular Alloimmunity in Hemodialysis Patients: Data from a Randomized Controlled Pilot Trial
  58. The origin of the PB1 segment of swine influenza A virus subtype H1N2 determines viral pathogenicity in mice
  59. Differential Requirement for the IKKβ/NF-κB Signaling Module in Regulating TLR- versus RLR-Induced Type 1 IFN Expression in Dendritic Cells
  60. Human Responses to Influenza Vaccination Show Seroconversion Signatures and Convergent Antibody Rearrangements
  61. Mucosal Polyinosinic-Polycytidylic Acid Improves Protection Elicited by Replicating Influenza Vaccines via Enhanced Dendritic Cell Function and T Cell Immunity
  62. Model of influenza A virus infection: Dynamics of viral antagonism and innate immune response
  63. Turkey Versus Guinea Pig Red Blood Cells: Hemagglutination Differences Alter Hemagglutination Inhibition Responses Against Influenza A/H1N1
  64. Cell death in pandemic and seasonal influenza viruses (VIR2P.1027)
  65. Suppression of Innate Immunity by Orthomyxoviruses
  66. Distinct Cross-reactive B-Cell Responses to Live Attenuated and Inactivated Influenza Vaccines
  67. Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine Correlate With the Kinetics and Magnitude of Interferon Signaling in Children
  68. Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge
  69. Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets
  70. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge
  71. MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies
  72. Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses
  73. Protection against Lethal Influenza with a Viral Mimic
  74. Glycosylations in the Globular Head of the Hemagglutinin Protein Modulate the Virulence and Antigenic Properties of the H1N1 Influenza Viruses
  75. Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs
  76. Substitutions T200A and E227A in the Hemagglutinin of Pandemic 2009 Influenza A Virus Increase Lethality but Decrease Transmission
  77. Induction of ICOS+CXCR3+CXCR5+ TH Cells Correlates with Antibody Responses to Influenza Vaccination
  78. H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice
  79. Accumulation of CD11b+Gr-1+ cells in the lung, blood and bone marrow of mice infected with highly pathogenic H5N1 and H1N1 influenza viruses
  80. Species-Specific Inhibition of RIG-I Ubiquitination and IFN Induction by the Influenza A Virus NS1 Protein
  81. Mouse Dendritic Cell (DC) Influenza Virus Infectivity Is Much Lower than That for Human DCs and Is Hemagglutinin Subtype Dependent
  82. Human Monoclonal Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses
  83. Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes
  84. Suppression of the antiviral response by an influenza histone mimic
  85. Major Histocompatibility Complex Class II Expression and Hemagglutinin Subtype Influence the Infectivity of Type A Influenza Virus for Respiratory Dendritic Cells
  86. The M Segment of the 2009 New Pandemic H1N1 Influenza Virus Is Critical for Its High Transmission Efficiency in the Guinea Pig Model
  87. Host- and Strain-Specific Regulation of Influenza Virus Polymerase Activity by Interacting Cellular Proteins
  88. Programming the magnitude and persistence of antibody responses with innate immunity
  89. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease
  90. Macaque Proteome Response to Highly Pathogenic Avian Influenza and 1918 Reassortant Influenza Virus Infections
  91. Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models
  92. NF- B RelA Subunit Is Crucial for Early IFN-  Expression and Resistance to RNA Virus Replication
  93. Extrapulmonary tissue responses in cynomolgus macaques (Macaca fascicularis) infected with highly pathogenic avian influenza A (H5N1) virus
  94. Complete-Proteome Mapping of Human Influenza A Adaptive Mutations: Implications for Human Transmissibility of Zoonotic Strains
  95. Innate immune evasion strategies of influenza viruses
  96. 1918 and 2009 H1N1 influenza viruses are not pathogenic in birds
  97. Matrix Protein 2 of Influenza A Virus Blocks Autophagosome Fusion with Lysosomes
  98. The NS1 Protein of the 1918 Pandemic Influenza Virus Blocks Host Interferon and Lipid Metabolism Pathways
  99. Influenza A Virus NS1 Targets the Ubiquitin Ligase TRIM25 to Evade Recognition by the Host Viral RNA Sensor RIG-I
  100. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus
  101. Experimental Infection of Pigs with the Human 1918 Pandemic Influenza Virus
  102. Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza
  103. The Unique IR2 Protein of Equine Herpesvirus 1 Negatively Regulates Viral Gene Expression
  104. The EICP27 protein of equine herpesvirus 1 is recruited to viral promoters by its interaction with the immediate-early protein
  105. A Negative Regulatory Element (Base Pairs −204 to −177) of the EICP0 Promoter of Equine Herpesvirus 1 Abolishes the EICP0 Protein's trans-Activation of Its Own Promoter
  106. The equine herpesvirus 1 EICP27 protein enhances gene expression via an interaction with TATA box-binding protein
  107. Direct interaction of TFIIB and the IE protein of equine herpesvirus 1 is required for maximal trans-activation function
  108. Interaction of the Equine Herpesvirus 1 EICP0 Protein with the Immediate-Early (IE) Protein, TFIIB, and TBP May Mediate the Antagonism between the IE and EICP0 Proteins
  109. Mapping the Sequences That Mediate Interaction of the Equine Herpesvirus 1 Immediate-Early Protein and Human TFIIB